Long-Term Outcomes in Real Life of Lumacaftor–Ivacaftor Treatment in Adolescents With Cystic Fibrosis
Authors:
Open Access
- 15 November 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 9
Abstract
Background: The combination of the CFTR corrector lumacaftor (LUM) and potentiator ivacaftor (IVA) has been labeled in France since 2015 for F508del homozygote cystic fibrosis (CF) patients over 12 years. In this real-life study, we aimed (i) to compare the changes in lung function, clinical (e.g., body mass index and pulmonary exacerbations) and radiological parameters, and in sweat chloride concentration before and after initiation of LUM/IVA treatment; (ii) to identify factors associated with response to treatment; and (iii) to assess the tolerance to treatment.Materials and Methods: In this tri-center, non-interventional, and observational cohort study, children (12–18 years old) were assessed prospectively during the 2 years of therapy, and retrospectively during the 2 years preceding treatment. Data collected and analyzed for the study were exclusively extracted from the medical electronic system records of the patients.Results: Forty adolescents aged 12.0–17.4 years at LUM/IVA initiation were included. The lung function decreased significantly during and prior to treatment and increased after LUM/IVA initiation, becoming significant after 2 years of treatment. LUM/IVA significantly improved the BMI Z-score and sweat chloride concentration. By contrast, there was no significant change in exacerbation rates, antibiotic use, or CT scan scores. Age at LUM/IVA initiation was lower in good responders and associated with greater ppFEV1 change during the 2 years of treatment. LUM/IVA was well-tolerated.Conclusion: In F508del homozygote adolescents, real-life long-term LUM/IVA improved the ppFEV1 trajectory, particularly in the youngest patients, nutritional status, and sweat chloride concentration but not exacerbation rates or radiological scores. LUM/IVA was generally well-tolerated and safe.Keywords
This publication has 34 references indexed in Scilit:
- Better Nutritional Status in Early Childhood Is Associated with Improved Clinical Outcomes and Survival in Patients with Cystic FibrosisThe Journal of Pediatrics, 2013
- Cystic fibrosis: Insight into CFTR pathophysiology and pharmacotherapyClinical Biochemistry, 2012
- Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809Proceedings of the National Academy of Sciences, 2011
- Pulmonary exacerbation: Towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trialsJournal of Cystic Fibrosis, 2011
- Recommandations françaises pour la réalisation et l’interprétation du test de la sueur dans le cadre du dépistage néonatal de la mucoviscidoseArchives de Pédiatrie, 2010
- Guidelines on the early management of infants diagnosed with cystic fibrosis following newborn screeningJournal of Cystic Fibrosis, 2010
- Year-to-year changes in lung function in individuals with cystic fibrosisJournal of Cystic Fibrosis, 2010
- The World Health Organization child growth standards: expected implications for clinical and epidemiological researchEuropean Journal of Pediatrics, 2008
- Cystic FibrosisNew England Journal of Medicine, 2005
- Cystic Fibrosis Mutations: Report from the French RegistryHuman Heredity, 1999